The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2017 / Apr / Making the Media of the Future – Today
Manufacture Bioprocessing Biopharma Sponsored

Making the Media of the Future – Today

Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.Biopharma manufacturing continues to advance and the demand for new innovations, such as more efficient cell culture media, is constant.

04/21/2017 1 min read

Share

In previous articles in this series, we heard about intensified perfusion systems from Delia Lyons (1), and about high-density cryopreservation from Jochen Sieck (2). Now, Lyons is joined by Jeremiah Riesberg (Senior Scientist, Perfusion Medium Development, Millipore Sigma, USA) to discuss a novel culture medium. The product, currently in beta testing with chosen clients, has been designed for the most challenging of applications – intensified perfusion at steady state – but is also applicable to a range of other processes.

Figure 1: Final medium (M3) could maintain a target cell density with a 40pL/cell/d with a 50 percent increase in specific productivity compared to prototype M1.

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. D Lyons, “An Intense Focus on Perfusion”, The Medicine Maker, 27 (2017). Available at: http://bit.ly/2mF5Dqp. JB Sieck, “Freezing Down Time in Bioprocessing”, The Medicine Maker, 28 (2017). Available at: http://bit.ly/2nK7wzD.

Recommended

Related Content

What Will It Take to Control Continuous Biomanufacturing
Bioprocessing Biopharma Research News
What Will It Take to Control Continuous Biomanufacturing?

November 2, 2026

2 min read

Review examines how PAT, model-based control, reinforcement learning, and digital twins could maintain product quality from perfusion culture through downstream purification

Choosing a Sterile Fill-Finish Partner
Outsourcing
Choosing a Sterile Fill-Finish Partner

October 22, 2026

5 min read

Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner

Can Clinical Trials Collect Less Data Without Compromising Safety?
Industry News Development & Clinical Regulation & Standards
Can Clinical Trials Collect Less Data Without Compromising Safety?

October 22, 2026

5 min read

Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.

Analytical Champions: Robert Wethman
Bioprocessing Biopharma Interviews
Analytical Champions: Robert Wethman

October 21, 2026

6 min read

Bristol Myers Squibb’s Robert Wethman discusses real-time spectroscopy, AI, and the next era of biopharmaceutical manufacturing

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: